CARA THERAPEUTICS INC (CARA)       8.59  +0.11 (+1.3%)

8.59  +0.11 (+1.3%)

US1407551092 - Common Stock

News Image
5 days ago - Market News Video

Oversold Conditions For Cara Therapeutics

News Image
14 days ago - Cara Therapeutics, Inc.

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new...

News Image
18 days ago - Cara Therapeutics, Inc.

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Significant reduction of itch...

News Image
20 days ago - Cara Therapeutics, Inc.

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

STAMFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new...

News Image
a month ago - Cara Therapeutics, Inc.

Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients with NP...

News Image
a month ago - Cara Therapeutics, Inc.

Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

Oral presentation will include data from the Phase 2 trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia...

News Image
a month ago - Cara Therapeutics, Inc.

Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated...

News Image
2 months ago - Cara Therapeutics, Inc.

Cara Therapeutics Reports Second Quarter 2022 Financial Results

– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the...

News Image
2 months ago - Cara Therapeutics, Inc.

Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

STAMFORD, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new...

News Image
2 months ago - Cara Therapeutics, Inc.

Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

STAMFORD, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new...

News Image
3 months ago - Cara Therapeutics, Inc.

Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and...